The action date for Salix Pharmaceuticals' marketing application for Plenvu was moved by the FDA to May 13 because the agency needs more time to evaluate additional data the company submitted. The drug is being assessed for bowel cleansing.
PDUFA date for Salix's Plenvu extended by FDA
Sign up for BIO SmartBrief
Biotechnology industry news
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.